Results 1 to 10 of about 30,368 (178)

Clarithromycin-based Helicobacter pylori eradication therapy is not associated with higher treatment failure compared with non-clarithromycin-based regimens in a tertiary referral hospital in Switzerland

Swiss Medical Weekly, 2023
BACKGROUND AND AIMS: Due to increasing antibiotic resistance, various Helicobacter pylori eradication regimens other than clarithromycin-based therapies have been proposed.
Tobias Braendli, Valeria Schindler, Dominique Laurent Braun, Fritz R. Murray, Juliane Marie Hente, Daniel Pohl   +5 more
doaj   +1 more source

Efficacy of quadruple therapy with clarithromycin based on faecal molecular antimicrobial susceptibility tests as first-line treatment for Helicobacter pylori infection: a protocol of a single-centre, single-blind, randomised clinical trial in China

BMJ Open, 2023
Introduction Helicobacter pylori is the most well-known risk factor for gastric cancer. Antibiotic resistance is the main reason for the failure of H.
Yan Li, Hao Wu, Jun Ye, Yujing Wang, Oulan Liao, Yaoyi Wu, Qin Du, Xiaochen Liu, Guochun Lou   +8 more
doaj   +1 more source

Levofloxacin-based therapy as an efficient alternative for eradicating Helicobacter pylori infection in Iran: a systematic review and meta-analysis

Journal of Global Antimicrobial Resistance, 2022
: Objectives: Despite excessive resistance of Helicobacter pylori to clarithromycin among the Iranian population, clarithromycin-based therapy is still prescribed in Iran. Recent studies have shown high rates of H. pylori eradication in patients treated
Masoud Keikha, Parvin Askari, Kiarash Ghazvini, Mohsen Karbalaei   +3 more
doaj   +1 more source

A nationwide cohort study suggests clarithromycin-based therapy for Helicobacter pylori eradication is safe in patients with stable coronary heart disease and subsequent peptic ulcer disease

BMC Gastroenterology, 2022
Background Clarithromycin-based therapy is important for Helicobacter pylori eradication treatment. However, clarithromycin may increase cardiovascular risk.
Yen-Chun Chen, Yi-Da Li, Ben-Hui Yu, Yi-Chun Chen   +3 more
doaj   +1 more source

Genetic Evolution of Mycobacterium abscessus Conferring Clarithromycin Resistance during Long-Term Antibiotic Therapy

Canadian Respiratory Journal, 2020
Objectives. Clarithromycin is recommended as the core agent for treating M. abscessus infections, which usually calls for at least one year of treatment course, facilitating the development of resistance.
Bing Li, Qi Guo, Yanhua Mao, Yuzhen Zou, Yongjie Zhang, Zhemin Zhang, Haiqing Chu   +6 more
doaj   +1 more source

Time-dependent effect of clarithromycin on pro-inflammatory cytokines in CRS [PDF]

Rhinology Online, 2022
Background: The purpose of this study was to assess the time-effect of clarithromycin on the inflammatory response in chronic rhinosinusitis (CRS), to further explore the use of macrolides in cell culture as a model for CRS, and its action on the immune ...
Ana Catarina Pratas, Zara Shaida, Jelena Gavrilovic, Carl Philpott   +3 more
doaj   +1 more source

Pattern of Primary Resistance of Helicobacter pylori to Clarithromycin among Pediatric Patients from North-Eastern Romania

Children, 2023
Background: Helicobacter pylori antibiotic resistance has increased worldwide and affects the effectiveness of current therapies. The recommended first-line empiric treatment should be tailored to the local clarithromycin resistance rate.
Oana-Maria Rosu, Nicoleta Gimiga, Roxana Popescu, Ileana Ioniuc, Carmen Daniela Rusu, Tatiana Clipa, Diana-Maria Florea, Doina-Anca Pleșca, Alexandru Nemtoi, Elena Tataranu, Gabriela Stefanescu, Smaranda Diaconescu   +11 more
doaj   +1 more source

Assessment of antimycobacterial activities of pure compounds extracted from Thai medicinal plants against clarithromycin-resistant Mycobacterium abscessus [PDF]

PeerJ, 2021
Background Infection with Mycobacterium abscessus is usually chronic and is associated with clarithromycin resistance. Increasing drug resistance is a major public-health problem and has led to the search for new antimycobacterial agents.
Auttawit Sirichoat, Irin Kham-ngam, Orawee Kaewprasert, Pimjai Ananta, Awat Wisetsai, Ratsami Lekphrom, Kiatichai Faksri   +6 more
doaj   +2 more sources

Effect of Clarithromycin on the Pharmacokinetics of Cabergoline in Healthy Controls and in Patients With Parkinson’s Disease

Journal of Pharmacological Sciences, 2006
.: Cabergoline is used in the treatment of Parkinson’s disease (PD). Clarithromycin is a potent inhibitor of CYP3A4 and P-glycoprotein and is often co-administered with cabergoline in usual clinical practice.
Akiko Nakatsuka, Masahiro Nagai, Hayato Yabe, Noriko Nishikawa, Takuo Nomura, Hiroyoko Moritoyo, Takashi Moritoyo, Masahiro Nomoto   +7 more
doaj   +1 more source

Effect of Clarithromycin on Enhancement of Doxorubicin-induced Cytotoxicity and Apoptosis in A549 Tumor-Cell Line

Journal of Mazandaran University of Medical Sciences, 2022
Background and purpose: Nowadays, multi-drug regimens or combination therapy are new approaches in cancer treatment that combine two or several therapeutic agents.
Mohammad Shokrzadeh, Fatemeh Shaki, Nahid Amani   +2 more
doaj